Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026)

Vertex Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• On a quarterly basis, Short-term Investments rose 14.89% year-over-year to $1.8 billion in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 14.89% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 1.49% from the prior year.
• Short-term Investments improved to $1.8 billion in Q1 2026 per VRTX's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.8 billion in Q1 2026 and bottomed at $274.5 million in Q4 2022.
• The 5-year median for Short-term Investments is $1.1 billion (2023), against an average of $1.1 billion.
• Across the five-year window, Short-term Investments plunged 62.39% in 2022 and surged 209.36% in 2023, its largest moves.
• Year by year, Short-term Investments stood at $274.5 million in 2022, then jumped by 209.36% to $849.2 million in 2023, then surged by 82.09% to $1.5 billion in 2024, then decreased by 1.49% to $1.5 billion in 2025, then advanced by 15.13% to $1.8 billion in 2026.
• Per Business Quant, the three latest VRTX Short-term Investments figures stand at $1.8 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025).